{"id":157996,"date":"2024-01-25T05:44:46","date_gmt":"2024-01-25T10:44:46","guid":{"rendered":"https:\/\/44.250.171.167\/?p=157996"},"modified":"2024-01-25T05:44:47","modified_gmt":"2024-01-25T10:44:47","slug":"laurus-labs-limited-q3-fy24-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy24-earnings-conference-call-insights\/","title":{"rendered":"Laurus Labs Limited Q3 FY24 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY24 Earnings Concall<\/strong><\/p>\n<ul>\n<li><strong>Business Performance<\/strong>\n<ul>\n<li>Gross margins remained resilient at over 52% for several quarters despite slower Q3 performance.<\/li>\n<li>EBITDA margins negatively impacted in Q3 due to higher expenses on growth projects and new initiatives.<\/li>\n<li>Q3 revenues increased 6% excluding large prior year CDMO order; overall declined 23% year-on-year to INR 1,195 crores.<\/li>\n<li>Underlying volume trends across businesses remain upbeat.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Growth Drivers<\/strong>\n<ul>\n<li>Building promising pipeline leveraging technology platform offerings.<\/li>\n<li>Gaining customer confidence through enabling capabilities.<\/li>\n<li>Investment in growth projects expected to accelerate future potential.<\/li>\n<li>Healthy order book and commercial execution to drive rebound from Q4FY24.<\/li>\n<li>Strategic priorities focused on long-term success.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Outlook<\/strong>\n<ul>\n<li>Formulations: Recovery in ARV business, growth in developed markets with new launches.<\/li>\n<li>Onco APIs: Strong 38% YTD growth; capacity expansion underway.<\/li>\n<li>Biosimilars &amp; Novel Biologics: Progress on NexCAR19 commercialization, gene therapy collaboration.<\/li>\n<\/ul>\n<\/li>\n<li><strong>CDMO Business Momentum<\/strong>\n<ul>\n<li>Baseline CDMO business healthy; project pipeline scaling up with new customers.<\/li>\n<li>Good RFP flow from big pharma and biotechs; advanced platform gaining confidence.<\/li>\n<li>Working on 60+ active projects, 10 products in commercial supply.<\/li>\n<li>Key CDMO capex projects on track across R&amp;D, manufacturing, crop sciences etc.<\/li>\n<li>Animal health unit started validation &amp; scaling up, fully contracted to big pharma.<\/li>\n<li>R&amp;D center to open by FY24 end to support new CDMO opportunities.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Biosimilars Business<\/strong>\n<ul>\n<li>Bio division sales up significantly to INR 131 crores in 9M FY24.<\/li>\n<li>Growth led by diversifying CDMO services across expanding customer base.<\/li>\n<li>Scaling enzyme engineering &amp; production capabilities into API projects.<\/li>\n<li>Downstream processing capacity up 20%; to peak revenues in FY25.<\/li>\n<li>Large R3 facility construction starting, adds 2 million liters fermentation.<\/li>\n<li>Phase 1 with 0.7-0.8 million liters to be completed in 24 months.<\/li>\n<li>Further phases to add capacity every 12 months.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Pipeline and Capacity Expansion Investments<\/strong>\n<ul>\n<li>R&amp;D spending at 4.8% of sales in 9M FY24; expected ~4.5% for full year.<\/li>\n<li>39 ANDA filings in US, 18 in EU, 21 in Canada etc.; 16 Para IV filings.<\/li>\n<li>Additional FDF capacity added, utilization expected from Q4FY24.<\/li>\n<li>Onco API capacity addition underway to strengthen leadership.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Financial Rebound and Growth<\/strong>\n<ul>\n<li>Putting weak quarters behind; confidence from order book and deliveries.<\/li>\n<li>In growth phase like 3 years ago before strong growth.<\/li>\n<li>Committing to better H2 than H1 as previously guided.<\/li>\n<li>Most gross margin uptick will flow to EBITDA based on leverage.<\/li>\n<li>Seeing revenue growth, not cost reductions driving profitability.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Capex Investments<\/strong>\n<ul>\n<li>Current capex focused on Synthesis and Bio divisions.<\/li>\n<li>Asset turns expected to improve from capex.<\/li>\n<li>Temporary deleveraging and margin impact.<\/li>\n<li>Investments will support growth in coming years.<\/li>\n<li>Not undertaking any major new capex currently.<\/li>\n<li>Looking to optimize spending without compromising growth.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Animal Health Business<\/strong>\n<ul>\n<li>Long-term contract for site capacity remains in place.<\/li>\n<li>Delayed qualification of facility and validations due to complexity.<\/li>\n<li>20 APIs need validation; doing 1+ per quarter to complete by FY26.<\/li>\n<li>Peak revenues expected in FY26, not FY25 as previously thought.<\/li>\n<\/ul>\n<\/li>\n<li><strong>CAR-T Therapy Progress<\/strong>\n<ul>\n<li>Started patient enrollment last month.<\/li>\n<li>Looking to accelerate access and adoption in India.<\/li>\n<li>Key milestone for novel pipeline and capabilities.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Non-capex Investments<\/strong>\n<ul>\n<li>Over INR 450 cr in Laurus Bio, ImmunoACT, IIT-Kanpur etc.<\/li>\n<li>Enabling expansion into new therapies like cell\/gene therapy.<\/li>\n<li>Will start contributing along with operational leverage.<\/li>\n<li>35-40 stores have achieved ROI showing profitable model.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Leveraging Core Capabilities<\/strong>\n<ul>\n<li>Utilizing existing infrastructure and scientific talent.<\/li>\n<li>Repurposing assets from legacy businesses.<\/li>\n<li>Focus on operational excellence and cost optimization.<\/li>\n<li>Prudent investments to support long-term growth.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY24 Earnings Concall Business Performance Gross margins remained resilient at over 52% for several quarters despite slower Q3 performance. EBITDA margins negatively impacted in Q3 due to higher expenses on growth projects and new initiatives. Q3 revenues increased 6% excluding large prior year CDMO order; overall declined [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":154818,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[898,3187,10169,9138],"class_list":["post-157996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-biotech","tag-biotechnology","tag-earnings","tag-pharma"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":155151,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":157996,"position":0},"title":"Laurus Labs Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"October 20, 2023","format":false,"excerpt":"Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY24 Earnings Concall Q2 FY24 Results Revenue declined 22% year-on-year to INR1,224 crores.. EBITDA was INR188 crores with 15.4% margin. Quarter-on-quarter growth rebounding in API and CDMO business. Healthy order book and partnerships for better H2 performance. New facilities to boost fermentation\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":139585,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":157996,"position":1},"title":"Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 31, 2023","format":false,"excerpt":"Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by growth in non-ARV revenues, especially CDMO and API, and recovery in ARV formulations that is expected to continue further. Q&A Highlights: [00:18:37] Sajal Kapoor asked about the anticipated\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139439,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy23-consolidated-revenue-jumps-by-50\/","url_meta":{"origin":157996,"position":2},"title":"Laurus Labs Limited Q3 FY23; Consolidated Revenue Jumps By 50%","author":"Hardik Bhandare","date":"January 30, 2023","format":false,"excerpt":"Laurus Labs Limited (NSE: LAURUSLABS) reported Revenue from Operations for Q3 FY23 of \u20b91,544.82 Crore up from \u20b91028.76 Crore year on year, a growth of 50%. Consolidated Net Profit of \u20b9277.85 Crore, up 31% from \u20b9154.97 Crore in the same quarter of the previous year. The Earnings per Share is\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ee793540-c7f0-4306-ad35-43e2d805547b-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177358,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","url_meta":{"origin":157996,"position":3},"title":"Laurus Labs Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 23, 2026","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":128735,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":157996,"position":4},"title":"Laurus Labs Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/83rl6ffkU9c Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY22 Earnings Concall Management Update: LAURUSLABS said that based on its healthy product pipeline, it continues to invest in FDF infrastructure. And brownfield expansion at Unit 2 is progressing as per expectation and is expected to add significant capacity to FDF\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177525,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-profit-up-174-amid-strong-growth-streak\/","url_meta":{"origin":157996,"position":5},"title":"Laurus Labs: Q3 Profit up 174% Amid Strong Growth Streak","author":"Staff Correspondent","date":"January 23, 2026","format":false,"excerpt":"Laurus Labs Limited (NSE: LAURUSLABS, BSE: 540222) shares closed at \u20b91,017.15 on Friday, up 1.21% following the release of its third-quarter financial results. The pharmaceutical manufacturer\u2019s shares reached an intraday high of \u20b91,032 before settling higher for the session. Market Capitalization The company's market capitalization stands at approximately \u20b9549.17 billion\u2026","rel":"","context":"In &quot;Health Care&quot;","block_context":{"text":"Health Care","link":"https:\/\/alphastreet.com\/india\/category\/healthcare-stocks\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/157996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=157996"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/157996\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/154818"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=157996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=157996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=157996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}